로딩 중...
52주 최고가 대비 41.9% 위치
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.
SEC 13F 공시 기준 · 2024-Q4
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $12.4M | $18.5M | $29.4M | $45.2M |
| 영업이익 | - | $-36.4M | $-54.5M | $-36.2M | $-26.9M |
| 당기순이익 | - | $-47.2M | $-59.4M | $-30.0M | $-39.2M |
| 잉여현금흐름 (FCF) | - | $-33.1M | $-51.2M | $-41.2M | $-18.9M |
| 수익성 비율 | |||||
| 영업이익률 | - | -293.9% | -294.3% | -122.9% | -59.7% |
| 순이익률 | - | -380.6% | -320.7% | -102.1% | -86.9% |
| ROE (자기자본이익률) | - | 26.8% | 219.3% | 116.0% | 115.8% |
| ROA (자산이익률) | - | -214.5% | -241.3% | -125.3% | -111.0% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 49.3% | 59.0% | 53.4% |
| EPS 성장률 (YoY) | - | -73.4% | 95.8% | 80.5% | - |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | - | - | - |
| PBR (주가순자산배수) | - | - | - | - | - |
| PSR (주가매출배수) | - | 50.0x | 30.0x | 10.7x | 6.8x |
| FCF Yield | - | -5.3% | -9.2% | -13.1% | -6.2% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | -0.01 | -0.06 | -0.91 | -1.02 |
| 유동비율 | - | 0.53 | 1.42 | 2.02 | 2.80 |
MOLINA HEALTHCARE INC
$179.86
$9.4B